A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly’s and Novo’s GLP-1 Duopoly
You probably already know that pharmaceutical powerhouses Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) dominate the…
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party?
Eli Lilly’s (NYSE: LLY) obesity drug, Zepbound, generated sales of $13.5 billion in 2025. Its Type 2 diabetes…